Efficacy and Safety Comparisons of Programmed Cell Death-1 vs Programmed Cell Death Ligand-1 Inhibitors in Patients with Cancer: A Systematic Review and Updated Meta-Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety Comparisons of Programmed Cell Death-1 vs Programmed Cell Death Ligand-1 Inhibitors in Patients with Cancer: A Systematic Review and Updated Meta-Analysis

Published:2023 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Yu Jun,Zhou Qiaoxia,Wang Guoqiang,Wang Hongwei,Yang Jinyu,Sun Xiaoran,Li Junjun,Shi Yezhen,Wang Jing,Guo Xiaofan,Zou Yiping,Xie Yongjie,Zhang Zhou,Zhang Yuzi,Cai Shangli,Hao Jihui

Publisher

Elsevier BV

Reference42 articles.

1. Immune Checkpoint Inhibitors in Cancer Therapy;Y Shiravand;Current Oncology,2022

2. Cancer immunotherapy using checkpoint blockade;A Ribas;Science,2018

3. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome;H O Alsaab;Frontiers in Pharmacology,2017

4. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action;N Zhang;Immunotherapy,2019

5. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma;T K Choueiri;New England Journal of Medicine,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP